November 30th 2023
The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.
November 25th 2023
From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.
November 21st 2023
In this CME, review the risks and clinical implications of intimate partner violence on women’s substance use and treatment.
November 14th 2023
Young men appear to be particularly susceptible to the effects of cannabis on schizophrenia.
November 3rd 2023
What is new in research on SUDs?
Dune and the Second Coming of Psychedelics in the United States
What does the movie Dune say about our society’s current relationship with psychedelics?
The ABCs of Vaping
What is vaping and when does it become a problem?
Chronic Adolescent THC Exposure: Mental Health Crisis?
Chronic adolescent exposure to THC and cannabis could lead to adverse mental health outcomes and impacted brain functioning.
The Opioid Crisis Is Neither a White Nor an Adult Problem
How can psychiatrists improve substance use treatment for Black and pediatric patients?
Are You Ready for the Annual Psychiatric Times World CME Conference?
At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.
The AMA’s 7 Recommendations for Reducing the Opioid Crisis
The American Medical Association is urging policymakers to act now to prevent further opioid overdose deaths.
Substance Use: The Importance of Advocacy
Understanding addiction through new, creative lenses can offer a fresh perspective.
A Vaccine to Treat Opioid Disorders: First Participant Enrolled in Trial
A vaccine that prevents oxycodone from entering the brain? This might be the safe, long-lasting, cost-effective solution for opioid use disorders.
Harnessing Harm-Reduction Methods to Combat the Opioid Crisis
Afghanistan Veterans Struggling With Mental Health
A recent survey found 70% of Afghanistan veterans have struggled with their mental health since serving.
To Treat or Not to Treat? The Conundrum of Likeability
Treating patients who may be perceived as “unlikeable” can be difficult.
Turning Over a New Leaf
As the seasons change and new possibilities open up, we also pause to remember the victims of September 11 and the ongoing opioid crisis.
The Case for Caution When Prescribing Benzodiazepines
Are benzodiazepine prescriptions contributing to the opioid overdose epidemic?
Reducing Opioid-Involved Overdose Deaths: States’ Prevention and Response Efforts
In this journal club, a medical student and an addiction psychiatrist review a thematic analysis of successful prevention efforts in states with declining rates of opioid-related overdose deaths.
I Had to Use
A patient presents with multiple substance use disorders super-imposed on mood and anxiety disorders. Where does a clinician even begin?
Developing a Novel Psychedelic: Salvinorin A
A kappa-opioid receptor with psychedelic effects, this potential agent for treatment-resistant depression and other disorders will be paired with a digital therapeutic for maximum efficacy.
10 keys to understanding the science of cannabinoids.
Anti-Fentanyl Vaccines as Medical Solutions to Overdose Deaths
Manufactured fentanyl is a major cause of overdoses for opioids and nonopiods. Can a vaccine immunize against overdose?
Fighting the Opioid Epidemic: The APA’s Call to Action
After the largest increase in overdose deaths in 50 years, the American Psychiatric Association sends out the call for improved substance use care.
First Participant Joins Opioid Use Disorder Treatment Study
Novel digital therapy modia will be evaluated in combination with sublingual buprenorphine/naloxone background therapy to see whether it is superior in reducing opioid use.
Treating Comorbid Substance Abuse and Trauma
The potential role of eye movement desensitization and reprocessing.
The Rise in Synthetic Cannabinoids and Cathinones
Cannabis has been heralded as a treatment for many conditions, but what about its psychiatric risks?
Rhode Island: The First State to Allow Harm Reduction Centers for Safe Drug Consumption
To combat drug overdoses, the Rhode Island governor signed a bill allowing people to consume pre-obtained drugs under safe, professional supervision of trained staff.
The Need for Better Crisis Prevention
Yes, we need better crisis management, but what we really need is better crisis prevention.
The Opioid Addiction Crisis and Racism: A Long, Troubled History
The enduring racial gap in the opiate addiction rate stems largely from racist 19th-century medical beliefs about Black bodies, coupled with substandard medical care provided to Black Civil War troops.
Patent Brings Psychiatry One Step Closer to Precision Medicine
Adial’s AD04 for the treatment of alcohol use disorder received a Notice of Allowance from the US Patent and Trademark Office.
A Bill to End the War on Drugs
The Drug Policy Reform Act, introduced today, intends to decriminalize drug use and possession, providing health-centered approaches and rehabilitation instead.
Varenicline and Tardive Dyskinesia in Schizophrenia
Lessons from Novel Harm Reduction Methods
How can understanding the opioid crisis in Canada inform strategies in the United States?
Vaping: What Psychiatrists Need to Know
Healthy lungs are at risk—what can you do as a clinician to help patients quit vaping?
2 Clarke Drive Cranbury, NJ 08512